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Summary: We have evaluated a new diagnostic kit for the determination of total estrogens in serum or plasma of
pregnant women by means of an enzyme-immuno-assay.
Within-run precision had a coefficient of variation of 4.7-4.9% for total estrogen concentrations of 400 to
2000 nmol/1. For the same range of concentrations, day-to-day precision was found to be 5.9—8.9%. Mean analytic
recovery of unconjugated estriol was 102%. Enzymatic hydrolysis of different estrogen conjugates was shown to be
virtually complete. The antiserum used in the assay has the same affinity for estrone, estradiol and estriol.
Preliminary clinical studies included 14 pregnant women. The results suggest that the determination of total estro-
gens in pregnancy plasma can be used to monitor fetoplacental function in much the same way as urine total estrogens
are used.
Evaluation eines Enzymimmunoassay zur Bestimmung der Gesamt-Östrogene im Serum
während der Schwangerschaft
Zusammenfassung: Ein neues Testbesteck für die Bestimmung der Gesamt-Östrogene in Serum oder Plasma schwange-
rer Frauen mittels Enzymimmunassay wird bewertet. Für Gesamt-Östrogen-Konzentrationen von 400 bis 2000 nmol/1
wurde für die Präzision in der Serie ein Variationskoeffizient von 4,7—4,9% gefunden, für die Präzision von Tag zu
Tag von 5,9—8,9%. Unkonjugiertes Östriol wurde zu 102% wiedergefunden. Die enzymatische Hydrolyse verschiede-
ner Östrogenkonjugate war offenbar vollständig. Das benutzte Antiserum hat gleiche Affinitäten für Östron, Östradiol
und Östriol.
Vorläufige klinische Studien umfaßten 14 Schwangere. Die Ergebnisse weisen daraufhin, daß die Bestimmung der Ge-
samt-Östrogene im Plasma Schwangerer in gleicher Weise wie die im Harn zur Überwachung der fetoplacentalen
Funktion angewandt werden kann.
Introduction Free estrogen in a hydrolyzed, diluted serum sample is
allowed to compete with an estriol-enzyme conjugate
It is generally agreed that determination of estrogens is f- a ̂ .̂  amQunt rf anti.estrogen serum. After incuba-
of clinical value in monitoring fetoplacental function. üon ̂  antibQdy i$ precipitated with a second anti-
Most laboratories measure total estrogen excretion in ^^ coupled tQ ceUulo$e (DASP® ) and the enzymatic
24-hour urine samples, activity is measured in the precipitated, bound fraction.
With the introduction of protein binding methods (1, The coupled enzyme used in the test is horse-radish
2, 3) accurate measurement of the low estrogen con- peroxidase (EC 1.11.1.7). Estrogen concentrations are
centrations in serum or plasma has become possible. At read from a calibration curve, obtained with ä manu-
present, several radip-immuno-assay kits for the measure- facturer-supplied estriol standard. In this study, we have
ment of estrogens in pregnancy serum or plasma, instead evaluated this test with regard to precision, recovery,
of urine, are commercially available. Recently, a new antibody affinity to different estrogens and practical and
commercial kit (Estronostjcon®) based on the work of clinical usefulness as compared with our routine total
Bosch et al. (4), has become available. estrogen determination in urine.
With this kft, total estrogens in serum are determined by i} Present address: R. K. Hospital, Dcpt. of Clinical Chemistry,
means of an enzyme-immuno-assay principle. Houttuinen 10, 3300 AL Dordrecht, The Netherlands.
0340-076X/80/0018-0327S2.00
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Materials and Methods
Equipment
All absorbance measurements were performed at 492 nm on
a Beckman model 25 spectrophotometer. For pipetting serum
samples, Helix pomatia extract and DASP® suspension we used
Eppendorf pipets with Eppendorf disposable tips. For the addi-
tion of antiserum and conjugate we used a Hamilton PB 600
repeating dispenser, equipped with a 2.5 ml syringe. All other
solutions were pipetted either with Seripettors® (Labora Mann^
heim GmbH, W. Germany) or normal volumetric pipets.
Estrogens and estrogen conjugates
All estrogens and estrogen conjugates used in the study were
purchased from Sigma Chemical Company. Names, catalogue
numbers and abbreviations that will be used in figure 2 and
table 4 are given in table 1.
Tab. 1. Estrogens and estrogen conjugates used in the study. The
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Routine urine total estrogen determination
The routine method which was used for urine total estrogen
determinations was an Auto-Analyzer method, identical to the
method described by Van Kessel et al. (5). This method is based
on ihelttrich technique (6).
Enzyme-immuno-assay for serum total estrogen determination
The enzyme-immuno-assay (Estronosticon®, Organon Technica
B. V., Oss, The Netherlands) was performed according to the
manufacturers' instructions. To reduce the reagent cost and the
necessary sample volume (500 μΐ of serum accord to the in-
struction manual) we reduced all volumes mentioned in the
instruction manual by half. All samples were analyzed in dupli-
cate.
Manual estrogen determinations
Stock solutions of estrogen conjugates, used in the hydrolysis
experiments were analyzed for their real estrogen content by the
method ofKreutzer & Meulendijk (7), based on the Kober reac-
tion.
Creatinine determination
Creatinine was determined by the method of the Dutch Stand^
ardizatiqn Committee on Clinical Chemistry.
Results
Precision
Six different sera from pregnant women were used for
precision studies. Six different urine samples from
pregnant women were used to compare the precisions of
both methods. For day-to-day precision studies, the sera
were analyzed 10 or 11 times in a period of about 2
weeks, and urines were analyzed 16 or 17 times within
a period of about 2 months, during the studies, the
samples were kept at ^ 20 °C until needed. The results
are given in table 2.
Linearity
Linearity is mainly dependent on the amount of con-
jugated estrogens that can be hydrolyzed by the Helix
pomatia extract in one hour; after this step in the
analysis procedure, the hydrolyzed sample is diluted
until the estrogen concentration falls within the range
of the calibration curve (0.66-2.78 nmol/1). The
hydrolyzing capacities of the Helix pomatia extract
will be discussed later.
A representative example of a standard curve is shown
in figure 1.
Recovery
To 1 ml of 12 different serum samples from pregnant
women 50 μΐ of different stock estriol solutions were
added. All serum samples supplied with extra estriol
were allowed to equilibrate overnight and were analyzed
Tab. 2. Results of precision studies with human sera and urines. Serum samples were analyzed with the enzyme-immuno-assay, urine
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Fig. 1. Representative example of a standard curve, obtained
with the estriol standard supplied by the manufacturer.
together with the original samples. All samples were
analyzed in duplicate. Table 3 shows the results of these
, recovery studies. Mean analytic recovery was found to
be 102%.
Antiserum affinity for different estrogens
To check the antiserum affinity for the three most
important estrogens, estrone, estradiol and estriol, we
prepared standard solutions for each of the estrogens,
with concentrations similar to those for a normal
standard curve. Standard curves, obtained with the
three different estrogens are visualized in figure 2.
Hydrolysis with Helix pomatia extract
The Helix pomatia extract contains sulphatase and
glucuronidase. We checked the hydrolyzing capacities
of the extract by adding small volumes of six different





Fig. 2. Standard curves obtained with three different estrogens.
For abbreviations: see table 1.
extra conjugates were then analyzed together with the
original pool-serum for their estrogen concentration
according to the normal procedure. In this experiment
we used only estrone and estriol conjugates, since
estradiol in serum is predominantly in the uncon-
jugated form. The recoveries that were found for the
different conjugates are shown in table 4.
Tab. 4. Results of recovery studies with different estrogen con-
jugates. For abbreviations: see table 1.
conjugate to a human serum pool. Samples containing
Tab. 3. Results of recovery studies with unconjugated estriol.
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Preliminary clinical studies
The preliminary clinical studies included 14 pregnant
women. Gestational lengths at the beginning of the
studies ranged from 23 to 28 weeks. One pregnancy
was complicated by severe hypertension, another one
by severe maternal diabetes. The other 12 pregnancies
proceeded without serious complications. At 9.00 a. m.
during each 24 hour urine collection a blood sample
was taken for total estrogen analysis. This procedure











We calculated Spearman rank correlation coefficients to
demonstrate the presence or absence of a significant
trend in total estrogen value with increasing gestational
length. In each case the gestational length was taken as
one variable and either the total 24 hour urine estrogen
excretion, or urinary estrogen/creatinine ratio or serum
total estrogen concentration as the other. Table 5
summarized the results of these calculations for the
14 pregnancies.
Figures 3,4 and 5 show some representative examples
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Fig. 3. Examples of estrogen values during complicated pregnancies. Left: values for patient no. 2, the diabetic woman; Right: values
for patient no. 4, the hypertensive patient. Estrogen/creatinine ratios calculated from estrogens (μηιοΐ/ΐ) and creatinine
(mmol/1).
Tab. 5. Spearman rank correlation coefficients (Rs) for 14 pregnancies, with the gestational length as one variable and either urine or
serum estrogen value as the second variable.
Patient no. Test period
(weeks)




























































































































* In parentheses: number of observations within the test period.
** S: significant at ρ < 0.05 level. NS: not significant at ρ < 0.05 level. E/C = Estrogen/creatinine ratio
j. Ciin. Chem. Clin. Biochem. / Vol. 18,1980 /«No. 6
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Weeks of gestation
Fig. 4. Fluctuations in estrogen values during pregnancy. Closed
symbols: patient no. 14. Open symbols: patient no. 8.
Numbers left of the stroke: gestational length for patient
no. 14. Numbers right of the stroke: gestational length
for patient no. 8. Estrogen/creatinine ratios calculated
from estrogens (μηιοΐ/ΐ) and creatinine (mmol/l).
The left half of figure 3 illustrates the estrogen values
from a 34-year-old gravida 3 para 2 with severe insulin
dependent diabetes (patient no. 2). Estrogen values in
serum and urine were low, but echoscopic examination
indicated a normal growing fetus. At 35 weeks of
gestation, a live, premature infant, birthweight 2180 g,
was delivered by cesarian section. The right half of
figure 3 shows the estrogen values from a 30^-y ear-old
gravida 2 para 0 with severe hypertension (patient no. 4).
Again, estrogen values in serum and urine were low. In
this case only the serum estrogen concentrations showed
a significantly falling trend. On echoscQpic examination
fetal growth was found to be impaired and at 35 weeks
of gestation a dead fetus, weighing 800 g was delivered.
On microscopic examination approximately 20% of the
placenta appeared to be infarcted. Figure 4 shows the
course of estrogen values in patients no. 14 and 8, who
were hospitalized for threatened immature labor and
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Fig. 5. Fluctuations in estrogen values during normal pregnancy.
Closed symbols: patient no. 7. Open symbols: patient
no. 9. Estrogen/creatinine ratios calculated from estrogens
(jumol/1) and creatinine (mmol/1).
Both pregnancies continued without further complica-
tions and both patients were delivered of healthy
infants. Finally, figure 5 illustrates two normal preg-
nancies (patients no. 7 and 9), resulting in full term,
normal-birthweight infants.
Discussion
We have evaluated a new commercially available enzyme-
immuno-assay for determination of total estrogens in
serum or plasma.
The precision studies performed in urine with our
routine Auto-Analyzer method and in serum with the
new assay, show that both methods have comparable
within-run precisions, whereas the serum assay has a
better day-to-day precision. The coefficients of variation
we found for the serum assay are comparable with values
reported in the literature for radio-immuno-assay proce-
dures (8,9).
The recovery of added estriol was good; mean analytical
recovery for all experiments was found to be 102%. One
sample (no. 5 in table 3) showed a low recovery of
59%. We have no explanation for this.
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The manufacturer of the enzyme-immiino-assay kit
claims that the antiserum has equal affinity for estrone,
estradiol and estriol. This is confirmed by our experi-
ments with the standard solutions of each estrogen. The
standard curves obtained with each estrogen were
virtually equal.
Hydrolysis experiments were performed with estrogen
conjugates that are found predominantly in serum. The
results indicate that hydrolysis is virtually complete for
all conjugates tested, except for estriol-3-sulphate, which
shows a somewhat lower recovery. We have no explana-
tion for this observation. A saline solution of the same
conjugate was hydrolyzed completely.
The amounts of conjugates added to the serum pool
were sufficient to produce final concentrations above
the upper normal limit for full term pregnancies, as given
by the manufacturer (about 3500 nmol/1). Therefore, it
can be concluded that the Helix pomatia extract hydro-
lyzes virtually all conjugated estrogens present in a serum
sample.
It is of practical interest that the enzyme-immuno-assay
procedure is quite laborious. In particular, centrifugation
and washing procedures are time consuming when large
series are analyzed. On the other hand, many manual
procedures for urine total estrogen determinations are
also laborious, because of extraction and washing proce-
dures. With proper equipment we were able to analyze
30-40 samples in duplicate within one working day.
Similar values have been reported for radio-immuno-
assay procedures (8). With an Auto-Analyzer, 100—125
samples can be analyzed within one day, but because of
reagent preparation and starting up and calibration
procedures the instrument has a lagtime of about 21/2
hours, which makes it less suitable for small series. More-
over, the instrument is quite expensive (about 100,000
Dutch Guilders).
The total estrogen concentrations obtained with the
enzyme-immuno-assay are not directly comparable with
values obtained with commercially available radio-
immuno-assay kits, since these measure mostly only
one type of estrogen. In the work of Bosch et al. (4) the
authors have compared the enzyme-immuno-assay with
a radio-immuno^assay, using the same antibody. Both
methods showed a good correlation;
Our first clinical results suggest that total estrogens in
serum and in urine provide similar information with
respect to fetoplacental function. We have not always
found a significant rise in serum estrogens with increasing
gestational length in normal pregnancies, but this applies
to urine determinations as well. According to table 5
serum total estrogens and urine total estrogens showed
a similar result (Rs significant (S) or not significant (NS)
at the p < 0.05 level) in 10 out of 14 pregnancies. For
serum total estrogens and urine estrogen/creatinine ratio
the results were similar in 9 out of 14 pregnancies, while
both urine values showed similar results in 9 out of 14
pregnancies.
Though the occurrence of diurnal variations of blood
estrogens has been claimed (10), others (11,12) have
not been able to demonstrate ä significant diurnal
rhythm. In our studies, diurnal variation is unlikely to
have influenced the results, since all samples were taken
at the same time of the day, i. e. 9.00 a. m.
A disadvantage of using urine samples is the difficulty
of obtaining a reliable 24-hour collection. Though the
estrogen/creatinine ratio can be used to circumvent this
problem (13), it has been shown that clearances of
estrogen and creatinine can vary independently in cases
of complicated pregnancy (14). Because of this, and
because of the results of this study, we feel that the
enzyme-immuno-assay of total estrogens in serum can be
considered an attractive alternative to the determination
of total estrogens in urine for monitoring of the feto-
placental unit.
In contrast to methods for serum estrogen determina-
tions that use radioactive tracers, no permit or special
counting equipment is needed for the enzyme-immuno^
assay of serum total estrogens, which makes the method
more widely applicable.
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